• Publications
  • Influence
Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial
Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction and all three methods of platelet reactivity assessment showed a stronger antiplatelet effect in the placebo group and a greater prevalence of high platelets reactivity in patients receiving morphine.
Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial
This study is expected to provide essential evidence-based data on the impact of morphine on the absorption of ticagrelor in patients with myocardial infarction as well as to shed some light on the suspected connection between morphine use and antiplatelet activity in the same group of patients.
Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors.
New directions for pharmacotherapy in the treatment of acute coronary syndrome
Introduction of cangrelor and ezetimibe, and potentially future recognition of proprotein convertase subtilisin/kexin type 9 antibodies, are likely to alter the landscape of ACS pharmacotherapy.
Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines.
Comparison of the PEGASUS-TIMI 54 and COMPASS trial patient characteristics clearly shows that each of these treatment strategies should be addressed at different groups of patients, and DATTs complement each other rather than compete.
Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor
Identification of ACS patients who have the highest odds of HPR during the initial phase of treatment with ticagrelor is facilitated, and who could potentially benefit from alternative treatment strategies are facilitated.
A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated,
It is hypothesized that reduction of the ticagrelor maintenance dose 1 month after acute coronary syndrome and its continuation until 12 months after ACS may improve adherence to antiplatelet treatment due to better tolerability compared with the standard dose of ticgrelor.
Prevalence of electrocardiographic left ventricular hypertrophy among patients with coronary artery disease and diabetes mellitus
The co-occurrence of all assessed ECG-LVH criteria, including the three most frequently applied in clinical practice, is very low in diabetic CAD patients.
Diabetogenic effect of statins: a comprehensive review on the clinical relevance, underlying pathomechanisms and rationale for tailored statin therapy
Statins are potent hypolipidemic drugs effectively reducing low-density lipoprotein (LDL) cholesterol serum concentration, but also exerting a wide range of pleiotropic effects. In numerous clinical
Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors.
Dual antiplatelet therapy consisting of one of the P2Y12 receptor inhibitors in conjunction with aspirin is the mainstay of treatment for patients with acute coronary syndromes (ACS) and those